Citi lowered the firm’s price target on DexCom (DXCM) to $85 from $105 and keeps a Buy rating on the shares. The firm is cautious on medical ...

DexCom’s Fair Value Estimate has recently been revised downward, moving modestly from $102.08 to $100.54 per share. This change reflects subtle shifts in analyst sentiment. While the company still ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $99.3, a high estimate of $106.00, and a low estimate of $89.00. Marking an ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

Oct 24 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for third-quarter revenue and profit on Thursday, helped by resilient demand for its continuous ...

VIENNA--(BUSINESS WIRE)-- DexCom, Inc. (DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...

Editor's note: This article has been updated with clarifying comments from Dexcom. Glucose-monitoring specialist Dexcom made several announcements this year, including receiving FDA clearance for its ...

Dexcom CGM: The choice for improving health outcomes and cost-effectiveness across diabetes types Dexcom is presenting several abstracts during the five-day conference showcasing clinical and ...